贝那普利和贝尼地平联合治疗糖尿病肾病的临床疗效

目的观察贝那普利和贝尼地平联合治疗2型糖尿病肾病的临床疗效。方法将2012年1月至2013年1月中国人民解放军北京军区北戴河疗养院收治疗的90例2型糖尿病肾病患者依据随机数字表法分为三组:A组30例口服贝尼地平4 mg,B组30例口服贝那普利10 mg,C组30例口服贝尼地平4 mg和贝那普利10 mg。疗程12周,观察三组治疗前后血压、血糖和肾功能的变化以及不良反应情况。结果治疗12周后,三组患者收缩压、舒张压、24 h尿蛋白均较治疗前下降(P<0.01);三组治疗前后血尿素氮、血肌酐、肌酐清除率、血清电解质(K+)和空腹血糖比较差异均无统计学意义(P>0.05)。三组不良反应发生率比较差异无统计学意义(P>0.05)。结论贝那普利、贝尼地平长期单独治疗均可有效降低血压和减少尿蛋白,两者联用在治疗2型糖尿病肾病的治疗上可增加疗效并减少不良反应。

Study on the Clinical Efficacy of Combined Therapy of Benazepril Benidipine for Patients with Diabetic Nephropathy

Objective To observe the clinical efficacy of combined therapy of benazepril and benidipine for patients with type 2 diabetic nephropathy. Methods A total of 90 patients with type 2 diabetic nephropathy admitted in PLA Beijing Military Region Beidaihe Sanatorium from Jan. 2012 to Jan. 2013 were randomly divided into three groups ： group A （ patients were given 4 mg of Benidipine）, group B （ patients were given 10 mg of benazepril） ,and group C（patients were given 4 mg of benidipine and 10 mg of benazepril）. After an average of 12 weeks follow-up, blood pressure, blood sugar level, kidney function, and adverse reactions of the three groups were observed and studied. Results After 12 weeks of treatment, systolic pressure, diastolic pressure,24-h urinary protein of the three groups all decreased（P 〈 0.01 ）. In the three groups before and after treatment, levels of blood urea nitrogen, serum creatinine, creatinine clearance rate, serum electrolyte （ K＋ ） and fasting blood glucose had no statistically significant differences （ P 〉 0.05 ）. The incidence of adverse reactions of the three groups had no statistically significant difference （ P 〉 0.05 ）. Conclusion Long-term application of single benazepril, or benidipine can effectively lower the blood pressure and reduce urinary protein; while the combined therapy of the two drugs can improve the efficacy of the treatment for type 2 diabetic nephropathy and reduce adverse reactions.